On December 3, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that members of the management team will present the company at the following virtual conferences (Press release, BerGenBio, DEC 3, 2020, View Source [SID1234574330]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Nordic-American Life Science Conference

Global Markets Day section

Date: 3rd December 2020

Time: 8AM – 12PM EST

Further information can be found here: View Source
-americanlifescience.com/

DNB Nordic Healthcare Conference

The DNB Markets Session

Date: 15th December 2020

Time: Live webcasts from 9AM CET

Further information can be found here: View Source

The presentations will be made available at www.bergenbio.com after the events.